30 research outputs found
Systemic Treatment Approaches in Breast Cancer
Breast cancer is the most conmlon malignant tumor among women, with an
estimated 135,000 new cases and 58,000 recorded deaths per year in the Europeau
Community in 1990. With respect to the Netherlands, the most recent data of The
Netherlands Cancer Registry show an incidence of nearly 10.000 new cases of primary
breast cancer and about 3500 breast cancer deaths per year. In women breast
cancer comprises one-third (33,2%) of all types of cancer. Ultimately about one out
of 10 women wiII get breast cancer during her life and one out of every 22 women
wiII sooner or later die as a consequence of metastatic disease.
Among the solid tumors breast cancer is one of the few types of cancers sensitive to
different systemic treatment reginJens both with respect to endocrine- and
chemotherapy. Both treatment modalities are nowadays standard practice in the
treatment of breast cancer, either to achieve cure, or prolongation of (relapse-free)
survival in the adjuvant setting, or to palliate metastatic disease. The efficacy of the
different forms of systemic treatment is dependent on patients- and tumor
characteristics
Clinical experience with venlafaxine in the treatment of hot flushes in women with a history of breast cancer
Clinical experience with venlafaxine in the treatment of hot flushes in women with a history of breast cancer
OBJECTIVE: To obtain practical experience with venlafaxine for hot flushes
in breast cancer patients and incorporate this in a treatment protocol.
METHOD: Twenty-two women with a history of breast cancer (mean age 49.2
years, range 35-65) were referred for consideration of treatment with
venlafaxine for hot flushes. Patients received extensive information on
treatment with venlafaxine and were advised to self-monitor the frequency
of their hot flushes. RESULTS: Eight women did not start venlafaxine
because they had no postmenopausal complaints, were lost to follow-up, had
too low a frequency of hot flushes, or refused treatment. Eventually 14
women started venlafaxine. Two of them did not tolerate venlafaxine, four
reported some effect but stopped because of side effects, two women had no
effect whatsoever. Six women observed a clear ( > 50%) reduction in their
hot flush frequency that was maintained at a median follow-up of 13
months. CONCLUSION: The group of patients referred for treatment was more
heterogeneous and more patients dropped out because of side effects than
expected. Extensive patient education, patient selection and evaluation of
the treatment effect (by self-monitoring of hot flush frequency) are
mandatory to avoid useless (continuation of) treatment and to prepare
patients for side effects. Under these conditions, a substantial minority
of patients benefit from venlafaxine
Clinical experience with venlafaxine in the treatment of hot flushes in women with a history of breast cancer
Weekly low-dose mitoxantrone plus doxorubicin as second-line chemotherapy for advanced breast cancer
Weekly low dose mitoxantrone (3 mg/m2) plus doxorubicin (8 mg/m2) was administered as second-line chemotherapy to 33 patients with advanced breast cancer. Four out of 28 evaluable patients (14%) obtained a partial response with a median duration of 34 weeks (range 18-67+ weeks), while 8 patients (29%) showed stable disease with a median duration of 28 weeks (range 11+-60 weeks). Gastrointestinal toxicity and alopecia were mild. Grade II and III leukopenia occurred in 63% of the courses without serious infectious disease. Four patients experienced an asymptomatic drop of 16-20% in the left ventricular ejection fraction (LVEF) after relatively low cumulative doses of each drug, and one patient with a history of pericarditis carcinomatosa and mediastinal irradiation developed a heart failure. In conclusion, this second-line combination treatment had moderate activity in breast cancer and caused only few subjective side effects, especially with respect to gastrointestinal symptoms
Risk of endometrial cancer after tamoxifen treatment of breast cancer
Since large trials have been set up to assess whether tamoxifen decreases the risk of breast cancer in healthy women, it has become important to investigate the drug's potential adverse effects, including occurrence of endometrial cancer. We undertook a case-cont
Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer
Item does not contain fulltextPURPOSE: Better breast cancer prognostication may improve selection of patients for adjuvant therapy. We conducted a retrospective longitudinal study in which we investigated sera of high-risk primary breast cancer patients, to search for proteins predictive of recurrence-free survival. METHODS: Sera of 82 breast cancer patients obtained after surgery, but prior to the administration of adjuvant therapy, were fractionated using anion-exchange chromatography, to facilitate the detection of the low-abundant serum peptides. Selected fractions were subsequently analysed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS), and the resulting protein profiles were searched for prognostic markers by appropriate bioinformatics tools. RESULTS: Four peak clusters (i.e. m/z 3073, m/z 3274, m/z 4405 and m/z 7973) were found to bear significant prognostic value (P </= 0.01). The m/z 3274 candidate marker was structurally identified as inter-alpha-trypsin inhibitor heavy chain 4 fragment(658-688) in serum. Except for the m/z 7973 peak cluster, these peaks remained independently associated with recurrence-free survival upon multivariate Cox regression analysis, including clinical parameters of known prognostic value in this study population. CONCLUSION: Investigation of the postoperative serum proteome by, e.g., anion-exchange fractionation followed by SELDI-TOF MS analysis is promising for the detection of novel prognostic factors. However, regarding the rather limited study population, validation of these results by analysis of independent study populations is warranted to assess the true clinical applicability of discovered prognostic markers. In addition, structural identification of the other markers will aid in elucidation of their role in breast cancer prognosis, as well as enable development of absolute quantitative assays
Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients
Contains fulltext :
70104tjan-heijnen.pdf (publisher's version ) (Open Access)BACKGROUND: Better breast cancer prognostication may improve selection of patients for adjuvant therapy. We conducted a retrospective follow-up study in which we investigated sera of high-risk primary breast cancer patients, to search for proteins predictive of recurrence free survival. METHODS: Two sample sets of high-risk primary breast cancer patients participating in a randomised national trial investigating the effectiveness of high-dose chemotherapy were analysed. Sera in set I (n = 63) were analysed by surface enhanced laser desorption ionisation time-of-flight mass spectrometry (SELDI-TOF MS) for biomarker finding. Initial results were validated by analysis of sample set II (n = 371), using one-dimensional gel-electrophoresis. RESULTS: In sample set I, the expression of a peak at mass-to-charge ratio 9198 (relative intensity 20), identified as haptoglobin (Hp) alpha-1 chain, was strongly associated with recurrence free survival (global Log-rank test; p = 0.0014). Haptoglobin is present in three distinct phenotypes (Hp 1-1, Hp 2-1, and Hp 2-2), of which only individuals with phenotype Hp 1-1 or Hp 2-1 express the haptoglobin alpha-1 chain. As the expression of the haptoglobin alpha-1 chain, determined by SELDI-TOF MS, corresponds to the phenotype, initial results were validated by haptoglobin phenotyping of the independent sample set II by native one-dimensional gel-electrophoresis. With the Hp 1-1 phenotype as the reference category, the univariate hazard ratio for recurrence was 0.87 (95% CI: 0.56 - 1.34, p = 0.5221) and 1.03 (95% CI: 0.65 - 1.64, p = 0.8966) for the Hp 2-1 and Hp 2-2 phenotypes, respectively, in sample set II. CONCLUSION: In contrast to our initial results, the haptoglobin phenotype was not identified as a predictor of recurrence free survival in high-risk primary breast cancer in our validation set. Our initial observation in the discovery set was probably the result of a type I error (i.e. false positive). This study illustrates the importance of validation in obtaining the true clinical applicability of a potential biomarker